Drugs / Penplimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06886347 | Jul 2023 → Apr 2026 overdue | nasopharyngeal carcinoma | Chen Xiaozhong | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Penplimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06886347 ↗ |
| Known as | Penplimab Injection | “Penplimab Injection: Intravenous infusion of Penplimab 200 mg Q3W, with a 3-week treatment cycle.” NCT06886347 ↗ |
| Route | Intravenous | “Intravenous infusion of Penplimab 200 mg Q3W” NCT06886347 ↗ |